Trial · NCT01611571
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Spine Bone Density | Active Risedronate Active Teriparatide | 6.95 | Standard Deviation 1.9 | % change in LS BMD | |
| Change in Spine Bone Density | Active Risedronte Placebo Teriparatide | 3.76 | Standard Deviation 1.8 | % change in LS BMD | |
| Change in Spine Bone Density | Placebo Risedronate Active Teriparatide | 5.68 | Standard Deviation 1.9 | % change in LS BMD | |
| Change in Hip Bone Density | Active Risedronate Active Teriparatide | 3.86 | Standard Deviation 1.1 | % change in TH BMD | |
| Change in Hip Bone Density | Active Risedronte Placebo Teriparatide | 0.82 | Standard Deviation 0.95 | % change in TH BMD | |
| Change in Hip Bone Density | Placebo Risedronate Active Teriparatide | 0.29 | Standard Deviation 0.95 | % change in TH BMD | |
| Change in Forearm Bone Density | Active Risedronate Active Teriparatide | 1.6 | Standard Deviation 0.6 | % change in 1/3 Radius BMD | |
| Change in Forearm Bone Density | Active Risedronte Placebo Teriparatide | 0.11 | Standard Deviation 0.77 | % change in 1/3 Radius BMD | |
| Change in Forearm Bone Density | Placebo Risedronate Active Teriparatide | 0.02 | Standard Deviation 0.77 | % change in 1/3 Radius BMD | |
| New Morphometric Vertebral Fractures | Active Risedronate Active Teriparatide | 1 | vertebral fracture | ||
| New Morphometric Vertebral Fractures | Active Risedronte Placebo Teriparatide | 1 | vertebral fracture | ||
| New Morphometric Vertebral Fractures | Placebo Risedronate Active Teriparatide | 0 | vertebral fracture | ||
| Change in FN BMD at 18 Months | Active Risedronate Active Teriparatide | 8.45 | Standard Deviation 1.8 | % change in TH BMD | |
| Change in FN BMD at 18 Months | Active Risedronte Placebo Teriparatide | 0.5 | Standard Deviation 1.7 | % change in TH BMD | |
| Change in FN BMD at 18 Months | Placebo Risedronate Active Teriparatide | 3.89 | Standard Deviation 1.7 | % change in TH BMD |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01611571/results